The research community was put on the spotlight after the recent visit of Joe Biden to the cancer treatment center led by Clay Siegall. Seattle Genetics received a visit from the vice President and has since been the talk of how fast the company has been growing. Seattle genetics has been trying to create new drugs to widen its scope of cancer treatment. The company is set to enlarge its overall drug pipeline and embark on an additional hiring spree.
The move by Seattle Genetics can be regarded as an ambitious one. It makes Seattle as a lead center for cancer research. The company has produced its first commercialized drug Adcetris. The drug has been used on several treatment scenarios. Adcetris is today being tested in up to 70 trials and is used to treat up several types of lymphomas. The company has focused on taking a phase 3 of advanced clinical trials. Adcetris has been used as a frontline treatment for the newly diagnosed cancer Hodgkin lymphoma. According to Seattle Genetics’ CEO, the result from the trials is going to be the biggest and the best experienced by the company.
It is worth noting that the Adcetris drug has been approved by the FDA. The FDA accepted the Seattle Genetics license for Adcetris, a clear indication of the safety and effectiveness of the drug. Adcetris is a drug that focuses on treatment of lymphoma cells. It combine with the general immune system and antibody allowing the drug to target specific lymphoma cells also known as CD30.
Seattle Genetics is one of the top biotechnology companies in the world today. It has specialized in commercializing antibodies for treatment of cancers. Clay Siegall has led the company to paths of great success since he serves as the CEO. Having worked for several cancer treatment and research companies, Dr. Siegall has received adequate knowledge to help fight cancer. Siegall further holds a Bachelor of Science in Zoology and a Ph.D. in Genetics. Dr. Siegall has played a key role in the company regarding its funding. He has managed to pull resources from public and private institutions that have funded several cancer treatment endeavors made by the company.